EP2577270A1 - Method and device for measuring and monitoring concentration of substances in a biological fluid - Google Patents
Method and device for measuring and monitoring concentration of substances in a biological fluidInfo
- Publication number
- EP2577270A1 EP2577270A1 EP20110741089 EP11741089A EP2577270A1 EP 2577270 A1 EP2577270 A1 EP 2577270A1 EP 20110741089 EP20110741089 EP 20110741089 EP 11741089 A EP11741089 A EP 11741089A EP 2577270 A1 EP2577270 A1 EP 2577270A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- concentration
- biological fluid
- substances
- dialysis
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 176
- 239000000126 substance Substances 0.000 title claims abstract description 58
- 239000013060 biological fluid Substances 0.000 title claims abstract description 51
- 238000012544 monitoring process Methods 0.000 title claims abstract description 23
- 238000000502 dialysis Methods 0.000 claims abstract description 98
- 230000003287 optical effect Effects 0.000 claims abstract description 52
- 230000014759 maintenance of location Effects 0.000 claims abstract description 32
- 238000005259 measurement Methods 0.000 claims abstract description 27
- 230000001131 transforming effect Effects 0.000 claims abstract description 16
- 230000003595 spectral effect Effects 0.000 claims abstract description 14
- 238000004422 calculation algorithm Methods 0.000 claims abstract description 12
- 238000012552 review Methods 0.000 claims abstract description 11
- 238000001228 spectrum Methods 0.000 claims abstract description 10
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 238000004364 calculation method Methods 0.000 claims abstract description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 88
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 73
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 73
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 73
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 64
- 229940116269 uric acid Drugs 0.000 claims description 64
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 59
- 238000002835 absorbance Methods 0.000 claims description 55
- 239000004202 carbamide Substances 0.000 claims description 49
- 229940109239 creatinine Drugs 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 238000012545 processing Methods 0.000 claims description 11
- 229940045136 urea Drugs 0.000 claims description 10
- 238000013507 mapping Methods 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 230000035764 nutrition Effects 0.000 claims description 6
- 235000003715 nutritional status Nutrition 0.000 claims description 6
- 238000011481 absorbance measurement Methods 0.000 claims description 4
- 238000013079 data visualisation Methods 0.000 claims description 3
- 238000012800 visualization Methods 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract description 4
- 208000028208 end stage renal disease Diseases 0.000 abstract description 3
- 201000000523 end stage renal failure Diseases 0.000 abstract description 3
- 239000012530 fluid Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 238000010200 validation analysis Methods 0.000 description 16
- 239000002441 uremic toxin Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- 238000001631 haemodialysis Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000322 hemodialysis Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 201000005569 Gout Diseases 0.000 description 5
- 201000001431 Hyperuricemia Diseases 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000037157 Azotemia Diseases 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 4
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 3
- 108010046334 Urease Proteins 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 208000016463 Wild type ABeta2M amyloidosis Diseases 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000003339 best practice Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 230000005518 electrochemistry Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 108010024957 Ascorbate Oxidase Proteins 0.000 description 1
- 238000010989 Bland-Altman Methods 0.000 description 1
- 206010005133 Bleeding tendencies Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108010077078 Creatinase Proteins 0.000 description 1
- 102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
- 101710128029 Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 238000007375 Jaffe assay Methods 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 108010060059 Sarcosine Oxidase Proteins 0.000 description 1
- 102000008118 Sarcosine oxidase Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940000032 cardiovascular system drug Drugs 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 238000010978 in-process monitoring Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000001008 quinone-imine dye Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000010248 tubular secretion Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- ZNOKGRXACCSDPY-UHFFFAOYSA-N tungsten trioxide Chemical compound O=[W](=O)=O ZNOKGRXACCSDPY-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
- G01N21/85—Investigating moving fluids or granular solids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/01—Arrangements or apparatus for facilitating the optical investigation
- G01N21/03—Cuvette constructions
- G01N21/05—Flow-through cuvettes
Definitions
- This invention relates to a novel method and a device for measuring and monitoring quantitatively concentrations of substances in a biological fluid and removal of uremic retention solutes utilizing UV-absorbance measurements during dialysis. More specifically, the present invention relates to an optical method utilizing optical spectrum, preferable UV- spectrum and UV-absorbance, preferable UV-absorbance of the spent dialysate, and a specific model, including a unique set of optical spectral components at certain wavelengths, to determine and to monitor, preferable on-line, the concentration and removal of the hardly diffusible uremic retention solutes like protein bound uremic toxins and middle molecules such as beta2-microglobulin (B2M) or easily diffusible uremic retention solutes like urea, creatinine or urea acid having small molecular weight.
- B2M beta2-microglobulin
- the uremic syndrome is attributed to the progressive retention of a large number of compounds, which under normal conditions are excreted by healthy kidneys. These compounds are called uremic retention solutes, or uremic toxins, when they interact negatively with biologic functions.
- the uremic syndrome is a complex principle favorintoxication" of the retention of waste products resulting in multifactorial problems where disturbances in several metabolic functions are reflected in clinical problems.
- organs and organ systems are affected: cardio-vascular system (hypertension, pericarditis and heart failure), peripheral nervous system (polyneuropathy), central nervous system (poor memory, loss of concentration and slower mental ability), hematology (anemia, bleeding tendencies), coagulation, immune status (immunosupression), nausea, vomiting etc.
- uremic toxins are divided into three groups: 1) small molecules (MW ⁇ 500 Da); 2) middle molecules (MW > 500 Da); 3) protein-bound solutes.
- uremic toxins have effect to the patient by many different ways and extent, and to ensure the best survival, quality of the treatment and the quality of life for the dialysis patients monitoring of several uremic toxins is essential.
- Small molecular weight solutes (MW ⁇ 500 g/mol): urea, creatinine, uric acid, guanidine - ADMA (asymmetric dimethylarginine), phosphate.
- Urea is a small, water soluble molecule with a molecular weight of 60 Da.
- Urea is the major end product of protein nitrogen metabolism in humans. It constitutes the largest fraction of the non - protein nitrogen component of the blood. Urea is produced in the liver and excreted through the kidneys in the urine. Consequently, the circulating levels of urea depend upon protein intake, protein catabolism and kidney function. Elevated urea levels can occur with dietary changes, diseases which impair kidney function, liver disease, congestive heart failure, diabetes and infection.
- the most common method for urea determination is the enzymatic method by the enzyme urease.
- urea is hydrolyzed in the presence of water and urease to produce ammoniaand carbon dioxide.
- GLDH glutamate dehydrogenase
- NADH reduced nicotinamide adenine dinucleotide
- the reaction is monitored by measuring the rate of decrease in absorbance at 340 nm as NADH is converted to NAD.
- the calculations are based on the discovery of Tiffany, et al. that urea concentration is proportional to absorbance change over a fixed time interval.
- Creatinine is a de-composition by product of the energy producing compound, creatine phosphate.
- the amount of creatinine produced is fairly constant and is primarily a function of muscle mass. Creatinine is removed from the plasma by glomerular filtration and then excreted in the urine without any appreciable re-absorption by the tubules. Typically 7-10% of creatinine in the urine is derived from tubular secretion but this is increased in the presence of renal insufficiency. Because creatinine is endogenous and is freely filtered at the glomerulus, it is widely used to assess kidney function (Glomerular Filtration Rate or GFR) and is expressed either as a plasma concentration or renal clearance.
- GFR Gelular Filtration Rate
- Creatinine can be determined in several different ways: 1) Jaffe method [2]; 2) enzymatic colourimetric method.
- Jaffe method testing utilizes picric acid for the Jaffe Reaction to test for creatinine. It forms a colored bright orange-red complex that can be measured using spectroscopy.
- the enzymatic colourimetric determination of creatinine which largely eliminates interferences known to the Jaffe method.
- the series of enzyme catalyzed reactions involved in the assay system are as follows: firstly, the potential interference from endogenous creatine and sarcosine are eliminated by the reaction of creatine amidinohydrolase, sarcosine oxidase and catalase before creatinine is determined.
- the formation of the quinoneimine dye product results in an increase in absorbance at 550nm (530-570nm) which is directly proportional to the creatinine concentration in the sample.
- Ascorbate oxidase eliminates the influence of ascorbate in the sample.
- the demerits of the abovementioned methods to determine urea and creatinine include: 1) some compounds similar to urea and creatinine contained in the sample of biological fluid may affect the test accuracy; 2) the operation is complex, needs lots of agents which are hard to keep, and should be operated by professionals; 3) the sample must be de-protein pretreated; and 4) the necessary equipment is expensive.
- Uric acid a final product of the metabolism of purine, is very important biological molecule present in body fluids. It is mostly excreted from human body through the kidneys in the form of urine. The concentration of uric acid in blood increases when the source of uric acid increases or the kidney malfunctions. Hyperuricemia is a symptom when the uric acid concentration is above 7 mg/dL. Uric acid is hard to dissolve in blood and will crystallize when supersaturated. The uric acid crystallites deposit on the surface of skin, in joints, and especially in toes and results in gout. The analysis of the uric acid concentration in blood helps to diagnose gout.
- hyperuricemia In addition to gout, hyperuricemia is connected with lymph disturbance, chronic hemolytic anemia, an increase of nucleic acid metabolism and kidney malfunction. Elevated serum UA contributes to endothelial dysfunction and increased oxidative stress within the glomerulus and the tubulo-interstitium, with associated increased remodeling fibrosis of the kidney [3].
- a high level of serum UA, hyperuricemia has been suggested to be an independent risk factor for cardiovascular and renal disease especially in patients with heart failure, hypertension and/or diabetes [4-6] and has been shown to cause renal disease in a rat model [7].
- UA is mostly associated with gout but studies have implicated that UA affects biological systems [8] and also could influence risks of higher mortality in dialysis patients [9] but the pathogenic role of hyperuricemia in dialysis patients is not complete established [10]. High caloric foods and alcohol as well as disturbances of organs and tissues are the main causes of hyperuricemia and even gout. Harm can be prevented and reduced by an early diagnosis and monitoring.
- a simple and inexpensive detecting system helps patients to detect the uric acid concentration on their own.
- a method and apparatus for the quantitative determination of optically active substances, particularly uric acid, by UV-absorbance is proposed in WO2009071102 (US60/992156, 04.12.2007), Ivo Fridolin, et al.
- Uric acid can be determined in several different ways. Two of the most common methods are (1) reduction method by the reaction of uric acid with alkaline phosphotungstate, and (2) the enzymatic method by the enzyme urease.
- uric acid is estimated by reducing alkaline phosphotungstate to tungsten blue and measuring the colored product in a colorimeter.
- the demerits of this method include: 1) some compounds similar to uric acid and ascorbic acid contained in the sample of biological fluid affect the test accuracy; 2) the operation is complex, needs lots of agents which are hard to keep, and should be operated by professionals; 3) the sample must be de- protein pretreated; and 4) the necessary equipment is expensive.
- the second method detects uric acid by optical colorimetry and electrochemistry and is classified into uricase-ultraviolet absorption, uricase-peroxidase, uricase-catalase and uricase-electrode methods, wherein the former three methods make use of the color of reaction products and quantitatively detect uric acid of by colorimetry.
- the decrease in absorbance is proportional to the amount of uric acid initially present.
- the automatic bio- analyzers used in central bio-laboratories of hospitals detect uric acid by optical colorimetry.
- An improving system for quantification of biochemical components in biological fluids during analysis where a component reacts with aft analyte is described in US6121050, 19.09.2000 HAN, CHI-NENG ARTHUR.
- the blood sample should be pretreated to be serum or plasma first.
- the merits of the automatic bio-analyzers reside in mass detecting, automation and quickness.
- an automatic bio-analyzer cannot be applied in household detecting because it requires professionals to operate, is expensive, and is particularly hard to store the detecting agents.
- the uricase-electrode method detects uric acid by electrochemistry.
- the electrodes can be divided as enzymatic and non-enzymatic.
- the former produced by a complex production process is hard to store and thus is only suitable for research.
- the blood sample should be pretreated to be serum or plasma first.
- the merits of the automatic bio-analyzers reside in mass detecting, automation and quickness.
- an automatic bio-analyzer cannot be applied in real-time and household detecting because it requires professionals to operate, is expensive, and is particularly hard to store the detecting agents.
- Middle molecules (MW > 500 g/mol): P2-microglobulin, cytokines (interleukin 6), parathyroid hormon (PTH) - (at the same time belongs to the protein-bound group).
- Protein-bound solutes indoxyl sulfate, homocysteine, p-cresol, AGE products, hippuric acid.
- B2M ⁇ 2 -microglobulin (B2M) (MW 1 1 818 D) is the light chain of HLA class I complex and as such is expressed on all nucleated cells.
- B2M is normally found in low concentrations in the plasma. In end stage renal failure its concentration increases markedly secondary to reduced renal elimination. Uremia-related amyloid is to a large extent composed of B2M and is essentially found in the osteoarticular system and in the carpal tunnel. Uremia related amyloidosis becomes clinically apparent after several years of chronic renal failure and/or in the aged. B2M has become a frequently used marker for the dialytic removal of middle molecules. Behavior of B2M during dialysis is, however, not necessarily representative of that of other middle molecules. Hemodialysis with large pore membranes results in a progressive decrease of predialysis B2M concentrations and in a lower prevalence of dialysis-related amyloidosis and/or carpal tunnel syndrome.
- B2M is mainly determined by ELISA assay method.
- the method is automated as an automatic bio-analyzer, the merits of the ELISA itself reside in mass detecting discrepancy and complicacy of the method. It cannot be applied in routine or household detecting because it requires professionals to operate, is expensive, and there is hard to store the detecting agents. Great care has been taken to ensure the quality and reliability of the method but however, it is possible that in certain cases unusual results may be obtained due to high levels of interfering factors.
- HPLC high performance reverse liquid chromatography
- indoxyl sulfate has been determined by fluorescence detection (excitation 280 nm, emission 340 nm)
- hippuric acid has been analyzed by ultraviolet detection at 254 nm in the serum and in the spent dialysate (Dhondt, Vanholder et al. 2003) [14].
- the demerits of this method include: 1) separation of the compounds may be difficult due to similar properties which affects the test accuracy; 2) the operation is complex, needs lots of agents and should be operated by professionals; 3) the sample needs pretreatment for deproteinization; and 4) the necessary equipment is expensive.
- the merits of the described method are that it does not need blood samples, no disposables or chemicals, and is fast.
- the described method is general and does not specify methodology to measure exclusively a single compound and is meant to apply only for dialysis monitoring. Moreover, no results about the concentration measurements are presented. More exact description about the uric acid and urea measurements using the abovementioned method is given in a scientific papers (Uhlin, Lindberg et al. 2005) [21], (Uhlin, Fridolin et al. 2005) [20].
- Another method relates to a method for dialysis monitoring method and apparatus using near infrared radiation, described in W09819592, 14.05.1998, RIO GRANDE MEDICAL TECH INC.
- the merits of the described method are similar to that of the UV-radiation.
- the described method measures urea and creatinine by utilizing near infrared radiation spectrometry with different technical and optical considerations.
- near infrared radiation spectrometry the principial component analysis using calibration and prediction stage is described in US5886347.
- Another method, described in RU2212029, 10.09.2003, VASILEVSKIJ A M et al relies on the Beer-Lambert law and utilizes the millimolar extinction coefficients of the components in the spent dialysate.
- the example given in this invention describes concentration determination of urea, phosphate, creatinine and uric acid.
- the example is given only for one dialysis session which is a serious limitation and can not be applied for the general use.
- urea and phosphate do not absorb UV-radiation as incorrectly claimed in this application, and thus concentration measurement of urea and phosphate is impossible using this invention.
- concentration measurement of creatinine is not applicable using the Beer- Lambert law.
- LBM Lean Body Mass
- a new, simplified mapping of dialysis dose and nutrition is proposed by using only two parameters - Kt/V and nPNA, suitable for automatic and time-efficient way to review the performed HD strategy based on the data from on-line dialysate side dialysis monitors.
- the abovementioned novel method for quantitative concentration measurements of uremic retention solutes in the biological fluids combined with the new, simplified mapping of dialysis dose and nutrition, gives an added value for the real-time, automatic monitoring of dialysis patients.
- the purpose of the invention is, therefore, a new method and a device for measuring concentration of substances (e.g. middle molecular weight solutes - (MM) (MW > 500 g/mol): p2-microglobulin, Cytokines (Interleukin 6), Parathyroid hormon (PTH) - at the same time belongs to the protein-bound group, small molecular weight solutes - (MW ⁇ 500 g/mol): Urea, Creatinine, Uric acid, Guanidine -ADMA (asymmetric dimethylarginine), Phosphate) in biological fluids and monitoring removal of the said hardly and easily diffusible uremic retention solutes during dialysis.
- substances e.g. middle molecular weight solutes - (MM) (MW > 500 g/mol): p2-microglobulin, Cytokines (Interleukin 6), Parathyroid hormon (PTH) - at the same time belongs to the protein-bound group, small molecular weight
- the present invention relates to an optical method utilizing optical spectrum of the biological fluids and UV- absorbance, preferable UV-absorbance of the spent dialysate or the peritoneal liquid, and concentration calculation algorithm containing the transforming function to determine on the samples or on-line the concentration of the substances, which can be effected directly at the bed-side, real-time and which avoids the disadvantages caused by the analysis in a laboratory.
- the method and device determines the concentration of the substances in-vitro or on-line utilizing a measuring cuvette (cell) suitable for specified measurements.
- Another object of the present invention is to provide a novel and practical optical urea and creatinine measuring method and device which determines quantitatively concentration of the forementioned water soluble small molecular weight substances in the spent dialysate. Those concentration values can be represented directly and easily on the monitor or screen printed.
- the novel method and device does not require any chemical disposables, and can be easily made and mass-produced providing an environment-friendly optical method.
- Another object of the present invention is to provide a practical optical method and device determining quantitatively concentration or removal of the middle molecules and protein bound uremic toxins in the biological fluids. The determined values can be represented directly and easily on the monitor or screen printed.
- the method and device does not require any chemical disposables, neither expensive separation techniques, and can be easily made and mass-produced providing an environment-friendly optical method.
- a still further object of the present invention is to provide a method for assessing routine clinical monitoring in order to face risks of higher mortality in patients (e.g. in dialysis).
- a still further object of the present invention is to provide a novel, rapid, convenient and safe method for detecting concentration of substances in a liquid sample.
- the liquid sample can be directly dropped on the detecting cuvette for in-vitro measurements or sent a flowing stream of fluid through a flow-through cell for on-line monitoring.
- the method is suitable for household use when being applied to detect the concentration of substances in the biological fluids.
- Fig. 1 shows a block diagram of one embodiment of the invention.
- Fig. 2 shows a block diagram of another embodiment of the invention applied for substances in a biological fluid during dialysis.
- Fig. 3 shows the linear relationship between urea concentration measured by the known method (Predicted) and at the laboratory (Expected) for the "Calibration" group.
- Fig. 4 shows the linear relationship between the urea concentration estimated by the new method (Predicted) and at the laboratory (Expected) for the "Calibration” group.
- Fig. 5 shows the linear relationship between the urea concentration estimated by the known method (Predicted) and at the laboratory (Expected) for the "Validation" group.
- Fig. 6 shows the linear relationship between the urea concentration estimated by the new method (Predicted) and at the laboratory (Expected) for the "Validation" group.
- Fig. 7 shows the linear relationship between creatinine concentration measured by the known method (Predicted) and at the laboratory (Expected) for the "Calibration” group.
- Fig. 8 shows the linear relationship between creatinine concentration measured by the new method (Predicted) and at the laboratory (Expected) for the "Calibration” group.
- Fig. 9 shows the linear relationship between creatinine concentration estimated by the known method (Predicted) and at the laboratory (Expected) for the "Validation” group.
- Fig. 10 shows the linear relationship between creatinine concentration estimated by the new method (Predicted) and at the laboratory (Expected) for the "Validation” group.
- Fig. 11 shows the linear relationship between the uric acid concentration measured by the known method (Predicted) and at the laboratory (Expected) for the "Calibration” group.
- Fig. 12 shows the linear relationship between uric acid concentration measured by the new A method (Predicted) and at the laboratory (Expected) for the "Calibration” group.
- Fig. 13 shows the linear relationship between uric acid concentration measured by the new B method (Predicted) and at the laboratory (Expected) for the "Calibration" group.
- Fig. 14 shows the linear relationship between the uric acid concentration estimated by the known method (Predicted) and at the laboratory (Expected) for the "Validation” group.
- Fig. 15 shows the linear relationship between the uric acid concentration estimated by the new A method (Predicted) and at the laboratory (Expected) for the "Validation” group.
- Fig. 16 shows the linear relationship between the uric acid concentration estimated by the new B method (Predicted) and at the laboratory (Expected) for the "Validation” group.
- Fig. 14 shows the linear relationship between the uric acid concentration estimated by the known method (Predicted) and at the laboratory (Expected) for the "Validation” group.
- Fig. 15 shows the linear relationship between the uric acid concentration estimated by the new A method (Predicted) and at the laboratory (Expected) for the "Validation” group.
- Fig. 16 shows the linear relationship between the uric acid concentration estimated by the new B method (Predicted)
- 17 shows a new, simplified mapping of dialysis dose and nutrition applied by using only two parameters - Kt/V and nPNA, suitable for automatic and time-efficient way to review the performed HD strategy based on the data from on-line dialysate side dialysis monitor.
- Fig. 18 shows an example to estimate a parameter Lean Body Mass (LBM), suitable for automatic and time-efficient way to review the muscle mass and protein nutritional status of the HD patients based on the data from on-line dialysate dialysis monitor as comparison between the known blood based (LBM b) and the novel UV-absorbance method (LBM_uv).
- LBM Lean Body Mass
- Fig. 20 shows the linear relationship between the B2M concentration in the spent dialysate estimated by the UV absorbance at 314 nm (Predicted) and at the laboratory (Expected) for the total material.
- Fig. 1 shows a block diagram of one embodiment of the invention applied for determining content of the hardly or easily diffusible uremic retention solutes in the biological fluids. Another embodiment of the invention is shown in Fig. 2.
- the device is applied for determining the concentration of substances (uremic retention solutes) in a biological fluid during dialysis in spent dialysate 6.
- the device comprises spectrophotometer 7, a signal processing unit 8 for concentration calculation, a unit 9 for presenting concentration or treatment map 10 of the substance in the spent dialysate.
- the block diagram of the device according to one embodiment of the invention is shown in Fig. 1.
- the device for measuring concentration of a hardly diffusible uremic retention solute 5 in a biological fluid 1 comprises:
- an optical module 2 comprising a spectrophotometrical system, comprising a light source and a light detector;
- a measuring cuvette for holding a sample of the biological fluid so that the light can be led through the sample
- a signal processing module 3 comprising a data acquisition module and a spectra processing module
- the light source can be either a broadband light source or a narrowband light source. If broadband light source is used, either a broadband detector with a filter can be used, or narrowband detectors. According to one embodiment, the optical module is operating in the ultra violet region (wavelength range 190-330 nm).
- the measuring cuvette can be, e.g., adapted for in-vitro measurements, or designed for the on-line measurements.
- the signal or spectra processing module is adapted to utilize the raw UV absorbance values or slope of the natural logarithimic UV absorbance values vs time to execute a dialysis dose calculation algorithm.
- the signal or spectra processing module is adapted to utilize a unique set of optical spectral components at certain wavelengths, adapted to execute a concentration calculation algorithm comprising a transforming function calculating, preferable real-time, the concentration of the uremic retention solutes in the biological fluid.
- the transforming function in order to transform UV-absorbance (dimensionless) into uremic retention solute concentration in mg/L or mmol/L, has the form
- y is a dependent variable (i.e. uremic retention solute concentration in mg/L or mmol/L)
- bO is the intercept
- bi-s are the appropriate regression coefficients
- Al - Ai-s are the measured UV-absorbances at the certain wavelengths
- xi-s are other appropriate variables.
- the data representing module is adapted to execute a program for data representation and comprises or is connected to a data visualization module, e.g., a monitor, a display, or a printing device.
- a data visualization module e.g., a monitor, a display, or a printing device.
- the data visualization module is adapted for a new, simplified mapping of dialysis dose and nutrition is applied by using only two parameters - Kt V and nPNA, suitable for automatic and time-efficient way to review the performed HD strategy based on the data from on-line dialysate side dialysis monitors.
- a group of uremic patients on chronic thrice-weekly hemodialysis were included in the study at the Department of Dialysis and Nephrology.
- the dialysate flow was 500 mL/min and the blood flow varied between 245 to 350 mL/min.
- the type of dialysis machine used was Fresenius 4008H (Fresenius Medical Care, Germany).
- the optical module consisted of a double-beam spectrophotometer (SHIMATSU UV-2401 PC, Japan) with an accuracy of ⁇ 1% on the dialysate samples taken at predetermined times during dialysis. Spectrophotometric analysis over a wavelength range of 190 - 380 nm was performed by a cuvette with an optical path length of 1 cm.
- the data acquisition module consisted of a PC incorporated in the spectrophotometer using UV-PC software (UV-PC personal spectrophotometer software, version 3.9 for Windows).
- the obtained UV-absorbance values were processed and presented by a signal processing module using a known (uniwavelength) algorithm, and the novel (multiwavelength) algorithm by a specially developed application by a concentration calculation algorithm containing the transforming function calculating the concentration of certain substance in the biological fluid.
- the data representing module was either the computer screen or a printer.
- dialysate samples were taken during the dialysis. Pure dialysate was collected before the start of a dialysis session, used as the reference solution, when the dialysis machine was prepared for starting and the conductivity was stable.
- concentrations of the substances such as urea, creatinine and uric acid, were determined at the clinical chemistry laboratory using standardized methods. On the basis of the results the determination coefficient R 2 , systematic error (BIAS) and standard error (SE) were calculated for the known and new method using concentrations from the laboratory as the reference as:
- e is the i-th residual and N is the number of observations.
- the i-th residual was obtained as the difference between laboratory and optically determined parameter values for the i-th measurement.
- the results (see Results) obtained by the closest existing method for determination of the amount of waste products in the dialysis liquid during dialysis treatment described in W09962574, US6666840B1 is referred here as the contextknown method". Those results are compared to the results by the method subject to this invention noted as the contextnew method".
- Including new patients should be the most sensitive because of the possible different combination or composition of the UV-absorbing compounds filtered from the blood into the dialysate during the dialysis may influence the model accuracy. To test a such situation only a part of the patients were included into the "Calibration" group to create a model, and after that new patients not presented before were included into the "Validation” group to validate the model.
- Fig. 3 and Fig. 4 show the linear relationship between urea concentration measured by the known and new method (Predicted) and at the laboratory (Expected) for the "Calibration" group.
- the new method utilises an unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the water soluble small molecular weight substance urea obtained by building up the model on the "Calibration" group.
- the transforming function in order to transform UV-absorbance (dimensionless) into urea concentration [mmol/L], has the form
- Urea (t) [mmol/L] 1.00 + 6.28* A(t, 295nm) - 8.86* A(t, 320nm) - 0.529* A(t, 253nm)
- Urea (t) [mmol/L] is a dependent variable urea concentration in mmol/L at the time moment t
- A(t, ⁇ nm) are the measured variables, i.e. absorbances at certain wavelengths at the time moment t multiplied by the appropriate coefficients.
- Fig. 5 and Fig. 6 show the linear relationship between urea concentration measured by the known and new method (Predicted Urea) and at the laboratory (Expected Urea) for the "Validation" group including the material not included into the model build up.
- Fig. 7 and Fig. 8 show the linear relationship between creatinine concentration measured by the known and new method (Predicted Crea) and at the laboratory (Expected Crea) for the "Calibration" group.
- the R 2 is increased remarkably compared to the known method.
- the new method utilises an unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the water soluble small molecular weight substance creatinine obtained by building up the model on the "Calibration" group.
- the transforming function in order to transform UV-absorbance (dimensionless) into creatinine concentration [mmol/L], has the form
- Crea (t) [mmol/L] 31.7 + 231.2*A(t, 294nm) - 321.3* A(t, 314nm) -72.8* A(t, 283nm)
- Crea (t) [mmol/L] is a dependent variable creatinine concentration in mmol/L)
- A(t, ⁇ nm) are the measured variables, i.e. absorbances at certain wavelengths at the time moment t multiplied by the appropriate coefficients.
- Fig. 9 and Fig. 10 show the linear relationship between creatinine concentration estimated by the known and new method (Predicted Crea) and at the laboratory (Expected Crea) for the "Validation” group.
- the R 2 is increased remarkably utilizing the new method compared to the known method even for the "Validation" group including the material not included into the model build up.
- Fig. 1 1 show the linear relationship between uric acid concentration estimated by the known method (Predicted) and at the laboratory (Expected) for the "Calibration” group.
- Fig. 12 and Fig. 13 show the linear relationship between uric acid concentration estimated by the new methods (A and B) (Predicted) and at the laboratory (Expected) for the "Calibration” group.
- the R 2 is increased utilizing the new method compared to the known method even for the "Calibration" group.
- the new method A utilises an unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the water soluble small molecular weight substance uric acid obtained by utilizing measured UV-absorbance values, and building up the model on the "Calibration" group.
- the transforming function of this method called as “New A method”, in order to transform UV-absorbance (dimensionless) into uric acid concentration [mmol/L], has the form
- UA (t) [mmol/L] is a dependent variable uric acid concentration in mmol/L at the time moment t
- A(t, ⁇ nm) are the measured variables, i.e. absorbances at certain wavelengths at the time moment t multiplied by the appropriate coefficients.
- the new method B utilises an unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the water soluble small molecular weight substance uric acid obtained by utilizing the processed UV- absorbance values by Sawitsky-Golay method, and building up the model on the "Calibration" group.
- the transforming function of this method called as "New B method", in order to transform UV-absorbance (dimensionless) into uric acid concentration [mmol/L], has the form
- A_d(t, ⁇ nm) are the variables (measured and the processed UV-absorbance values by Sawitsky-Golay method), i.e. processed absorbances at certain wavelengths at the time moment t multiplied by the appropriate coefficients.
- Fig. 14 show the linear relationship between uric acid concentration estimated by the known method (Predicted) and at the laboratory (Expected) for the "Validation” group.
- Fig. 15 and Fig. 16 show the linear relationship between uric acid concentration estimated by the new methods (A and B) (Predicted) and at the laboratory (Expected) for the "Validation” group.
- the R 2 is increased remarkably utilizing the new method compared to the known method even for the "Validation" group including the material not included into the model build up.
- Table 3 Summary results for the different methods to measure concentration of the acid.
- Fig. 17 shows a new, simplified mapping of dialysis dose and nutrition applied by using only two parameters - Kt/V and nPNA, suitable for automatic and time-efficient way to review the performed HD strategy based on the data from on-line dialysate side dialysis monitor, utilizing the urea concentration determination method described above.
- Fig. 18 shows an example to estimate a parameter Lean Body Mass (LBM), suitable for automatic and time-efficient way to review the muscle mass and protein nutritional status of the HD patients based on the data from on-line dialysate dialysis monitor as comparison between the known blood based (LBM b) and the novel UV-absorbance method (LBM_uv), utilizing the creatinine concentration determination method described above.
- LBM Lean Body Mass
- the duration of the ol-HDF treatments varied between 180 to 270 minutes, the dialysate flow was 500 mL/min, the blood flow varied between 280-350 mL/min. All patients were dialyzed via artery-venous fistulas using a "two-needle" system.
- the auto sub system mode for calculation of the on-line prepared substitution volume varied between 12.2 to 29.7 liters per session.
- the linear relationship analysis for B2M utilizing UV absorbance values at the wavelength which yielded the strongest correlation (314 nm) and the concentrations from the laboratory. This led to a specific model which enabled transform the optical measurements into the B2M concentration values.
- the function in order to transform UV-absorbance (dimensionless) into the B2M concentration in mg/L, had the form:
- Table 4 summarises all results about the B2M concentrations as mean and standard deviation values (Mean +/- SD) from the standardised methods (Lab) and from the new method (UV).
- Table 4 Summary results about the concentration mean and standard deviation values (Mean +/- SD) from the standardised methods (Lab) and new method (UV), linear correlation coefficient (r) and the R-squared value (R ) between the uremic toxins concentration from the optical method and concentration measured at the laboratory, the accuracy (BIAS) and precision (SE) for the different methods to measure concentration of
- the removal of B2M from the optical measurements is estimated below to calculate the dialysis dose for B2M, being representative in its kinetic behavior of other MM and peptides of similar size.
- the dialysis dose for the B2M from blood, spKt/Vb_B2M and eKt/Vb_B2M can be calculated using the pre- and post- dialysis blood B2M concentrations (C 0 and C t ).
- the single pool volume Kt/V, spKt/Vb_B2M was calculated according to the formula proposed by Casino et al 2010 [1 1], as
- eKt/Vb _ B2M spKt/V p2m * T d /(T d + 11 ⁇ ) (4 where T d is the dialysis session length.
- the UV-absorbance value in the beginning, A 0 (9 min dialysate sample) and at the end of dialysis, A t were utilized at the wavelength which yielded the strongest correlation between B2M concentrations measured in the spent dialysate by the new method (by the UV absorbance) and at the laboratory (314 nm).
- the single pool volume Kt/V from the absorbance measurements, spKt/V a_B2M was calculated as
- Table 5 summarises all results about the dialysis dose for the B2M as eKt/V_B2M calculated using the pre- and post- dialysis blood B2M concentrations and the absorbance values from totally 20 HDF sessions.
- the linear correlation coefficient (r) and the R-squared value (R2) between the dialysis dose for B2M from the optical method and dialysis dose for B2M from the blood concentrations are given.
- the accuracy (BIAS) and precision (SE) for the optical method was calculated using dialysis dose for the B2M from blood as reference after bias correction.
- Table 5 Summary of dialysis dose as eKt/V_B2M, calculated by the TDC and the absorbance values on the tank dialysate sample (UV) , the linear correlation coefficient (r) and the R-squared value (R ) between the dialysis dose for B2M from the optical method and from the blood concentrations, the accuracy (BIAS) and precision (SE) for the optical method.
- the concentration of B2M from optical measurements is utilized below to calculate the total removed B2M, TR_B2M.
- Table 6 summarises all results about the dialysis dose for the B2M as the total removed B2M, TR_B2M, calculated using the B2M concentrations in the tank at the end of dialysis estimated at the laboratory (TDC), and by the UV-absorbance (UV) from totally 20 HDF sessions.
- the linear correlation coefficient (r) and the R-squared value (R2) between the dialysis dose for B2M from the optical method and dialysis dose for B2M from the blood concentrations are given.
- the accuracy (BIAS) and precision (SE) for the optical method was calculated using dialysis dose for the B2M from blood as reference after bias correction.
- Table 6 Summary of dialysis dose as TR B2M, calculated using using the B2M concentrations in the tank at the end of dialysis estimated at the laboratory (TDC) and by the UV-absorbance (UV), the linear correlation coefficient (r) and the R-squared value (R 2 ) between the dialysis dose for B2M from the optical method and from the blood concentrations, the accuracy (BIAS) and precision (SE) for the optical method.
- TDC UV-absorbance
- r linear correlation coefficient
- R 2 R-squared value
- WO2009071 102 Ivo Fridolin, Jana Jerotskaja, Kai Lauri and Merike Luman. Optical method and device for measuring concentrations of substances in biological fluids.
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
Method and device for monitoring removal of hardly or easily diffusible uremic retention solutes during dialysis and for measuring concentration of said substances in a biological fluid, and more specifically in the spent dialysate, for estimation of dialysis dose on dialysis patients. Measurements are performed optically utilizing spectrum of the biological fluid and a concentration calculation algorithm containing the transforming function, including a unique set of optical spectral components at certain wavelengths, to determine the concentration of the substances in specimens in-vitro or flowing fluids on-line. Method and device determines the concentration of the substances in-vitro or on-line utilizing a measuring cuvette suitable for specified measurements. This enables monitoring quantitatively concentrations of substances in a biological fluid and calculation of the dialysis dose for hardly or easily diffusible uremic retention solutes, suitable for automatic and time-efficient way to review the dialysis quality delivered to the end stage renal disease patients.
Description
Method and device for measuring and monitoring concentration of substances in a biological fluid
Technical field
This invention relates to a novel method and a device for measuring and monitoring quantitatively concentrations of substances in a biological fluid and removal of uremic retention solutes utilizing UV-absorbance measurements during dialysis. More specifically, the present invention relates to an optical method utilizing optical spectrum, preferable UV- spectrum and UV-absorbance, preferable UV-absorbance of the spent dialysate, and a specific model, including a unique set of optical spectral components at certain wavelengths, to determine and to monitor, preferable on-line, the concentration and removal of the hardly diffusible uremic retention solutes like protein bound uremic toxins and middle molecules such as beta2-microglobulin (B2M) or easily diffusible uremic retention solutes like urea, creatinine or urea acid having small molecular weight.
Background of the invention
Monitoring of the important biological constituents in biological fluids from the medical point of view can prevent serious pathological conditions and decrease mortality of patients. There is a need for a simple, compact, inexpensive, mobile, reliable method for measuring concentration of water soluble middle and small molecular weight uremic retention solutes like beta2-microglobulin (B2M), urea or creatinine in the spent dialysate for estimation of dialysis dose and nutritional status (protein nitrogen appearance and lean body mass) on dialysis patients.
The uremic syndrome is attributed to the progressive retention of a large number of compounds, which under normal conditions are excreted by healthy kidneys. These compounds are called uremic retention solutes, or uremic toxins, when they interact negatively with biologic functions. The uremic syndrome is a complex„intoxication" of the retention of waste products resulting in multifactorial problems where disturbances in several metabolic functions are reflected in clinical problems. Several organs and organ systems are affected: cardio-vascular system (hypertension, pericarditis and heart failure), peripheral nervous system (polyneuropathy), central nervous system (poor memory, loss of concentration and slower mental ability), hematology (anemia, bleeding tendencies), coagulation, immune status (immunosupression), nausea, vomiting etc.
European Society of Artificial Organs (ESAO) and European Uremic Toxin Work Group (EUTox) have done a lot of research and have had a great success to identify uremic toxins
and to connect uremic toxins with the clinical status of the renal patients (Vanholder, De Smet et al. 2003) [22].
In the medical literature the uremic toxins are divided into three groups: 1) small molecules (MW < 500 Da); 2) middle molecules (MW > 500 Da); 3) protein-bound solutes.
Different uremic toxins have effect to the patient by many different ways and extent, and to ensure the best survival, quality of the treatment and the quality of life for the dialysis patients monitoring of several uremic toxins is essential.
Clinically, the most discussed molecules connected to uremic toxicity are the following: Small molecular weight solutes (MW < 500 g/mol): urea, creatinine, uric acid, guanidine - ADMA (asymmetric dimethylarginine), phosphate.
Urea is a small, water soluble molecule with a molecular weight of 60 Da. Urea is the major end product of protein nitrogen metabolism in humans. It constitutes the largest fraction of the non - protein nitrogen component of the blood. Urea is produced in the liver and excreted through the kidneys in the urine. Consequently, the circulating levels of urea depend upon protein intake, protein catabolism and kidney function. Elevated urea levels can occur with dietary changes, diseases which impair kidney function, liver disease, congestive heart failure, diabetes and infection.
The most common method for urea determination is the enzymatic method by the enzyme urease.
The enzyme methodology employed by a specific reagent is based on the following reaction: urea is hydrolyzed in the presence of water and urease to produce ammoniaand carbon dioxide. In the presence of glutamate dehydrogenase (GLDH) and reduced nicotinamide adenine dinucleotide (NADH), the ammonia combines with a-ketoglutarate (a-KG) to produce L-glutamate. The reaction is monitored by measuring the rate of decrease in absorbance at 340 nm as NADH is converted to NAD. To shorten and simplify the assay, the calculations are based on the discovery of Tiffany, et al. that urea concentration is proportional to absorbance change over a fixed time interval.
Creatinine is a de-composition by product of the energy producing compound, creatine phosphate. The amount of creatinine produced is fairly constant and is primarily a function of muscle mass. Creatinine is removed from the plasma by glomerular filtration and then excreted in the urine without any appreciable re-absorption by the tubules. Typically 7-10% of creatinine in the urine is derived from tubular secretion but this is increased in the presence of renal insufficiency. Because creatinine is endogenous and is freely filtered at the glomerulus, it is widely used to assess kidney function (Glomerular Filtration Rate or
GFR) and is expressed either as a plasma concentration or renal clearance. Elevated levels of plasma creatinine are associated with impaired renal function. The increase in serum creatinine is the result of uremic retention, but also can be due to muscle breakdown. Morbidity and mortality in hemodialyzed patients are positively correlated with serum creatinine. Creatinine is also a precursor of toxic compound methylguanidine. [1]
Creatinine can be determined in several different ways: 1) Jaffe method [2]; 2) enzymatic colourimetric method.
Jaffe method: testing utilizes picric acid for the Jaffe Reaction to test for creatinine. It forms a colored bright orange-red complex that can be measured using spectroscopy.
The enzymatic colourimetric determination of creatinine which largely eliminates interferences known to the Jaffe method. The series of enzyme catalyzed reactions involved in the assay system are as follows: firstly, the potential interference from endogenous creatine and sarcosine are eliminated by the reaction of creatine amidinohydrolase, sarcosine oxidase and catalase before creatinine is determined. In the final reaction sequence, the formation of the quinoneimine dye product results in an increase in absorbance at 550nm (530-570nm) which is directly proportional to the creatinine concentration in the sample. Ascorbate oxidase eliminates the influence of ascorbate in the sample.
The demerits of the abovementioned methods to determine urea and creatinine include: 1) some compounds similar to urea and creatinine contained in the sample of biological fluid may affect the test accuracy; 2) the operation is complex, needs lots of agents which are hard to keep, and should be operated by professionals; 3) the sample must be de-protein pretreated; and 4) the necessary equipment is expensive.
Uric acid, a final product of the metabolism of purine, is very important biological molecule present in body fluids. It is mostly excreted from human body through the kidneys in the form of urine. The concentration of uric acid in blood increases when the source of uric acid increases or the kidney malfunctions. Hyperuricemia is a symptom when the uric acid concentration is above 7 mg/dL. Uric acid is hard to dissolve in blood and will crystallize when supersaturated. The uric acid crystallites deposit on the surface of skin, in joints, and especially in toes and results in gout. The analysis of the uric acid concentration in blood helps to diagnose gout. In addition to gout, hyperuricemia is connected with lymph disturbance, chronic hemolytic anemia, an increase of nucleic acid metabolism and kidney malfunction. Elevated serum UA contributes to endothelial dysfunction and increased oxidative stress within the glomerulus and the tubulo-interstitium, with associated increased
remodeling fibrosis of the kidney [3]. A high level of serum UA, hyperuricemia, has been suggested to be an independent risk factor for cardiovascular and renal disease especially in patients with heart failure, hypertension and/or diabetes [4-6] and has been shown to cause renal disease in a rat model [7]. UA is mostly associated with gout but studies have implicated that UA affects biological systems [8] and also could influence risks of higher mortality in dialysis patients [9] but the pathogenic role of hyperuricemia in dialysis patients is not complete established [10]. High caloric foods and alcohol as well as disturbances of organs and tissues are the main causes of hyperuricemia and even gout. Harm can be prevented and reduced by an early diagnosis and monitoring.
A simple and inexpensive detecting system helps patients to detect the uric acid concentration on their own. As an example, a method and apparatus for the quantitative determination of optically active substances, particularly uric acid, by UV-absorbance, is proposed in WO2009071102 (US60/992156, 04.12.2007), Ivo Fridolin, et al.
Uric acid can be determined in several different ways. Two of the most common methods are (1) reduction method by the reaction of uric acid with alkaline phosphotungstate, and (2) the enzymatic method by the enzyme urease.
In the first method, uric acid is estimated by reducing alkaline phosphotungstate to tungsten blue and measuring the colored product in a colorimeter. The demerits of this method include: 1) some compounds similar to uric acid and ascorbic acid contained in the sample of biological fluid affect the test accuracy; 2) the operation is complex, needs lots of agents which are hard to keep, and should be operated by professionals; 3) the sample must be de- protein pretreated; and 4) the necessary equipment is expensive.
The second method detects uric acid by optical colorimetry and electrochemistry and is classified into uricase-ultraviolet absorption, uricase-peroxidase, uricase-catalase and uricase-electrode methods, wherein the former three methods make use of the color of reaction products and quantitatively detect uric acid of by colorimetry. The decrease in absorbance is proportional to the amount of uric acid initially present. The automatic bio- analyzers used in central bio-laboratories of hospitals detect uric acid by optical colorimetry. An improving system for quantification of biochemical components in biological fluids during analysis where a component reacts with aft analyte is described in US6121050, 19.09.2000 HAN, CHI-NENG ARTHUR.
The blood sample should be pretreated to be serum or plasma first. The merits of the automatic bio-analyzers reside in mass detecting, automation and quickness. However, an automatic bio-analyzer cannot be applied in household detecting because it requires
professionals to operate, is expensive, and is particularly hard to store the detecting agents. The uricase-electrode method detects uric acid by electrochemistry. The electrodes can be divided as enzymatic and non-enzymatic. The former produced by a complex production process is hard to store and thus is only suitable for research.
The blood sample should be pretreated to be serum or plasma first. The merits of the automatic bio-analyzers reside in mass detecting, automation and quickness. However, an automatic bio-analyzer cannot be applied in real-time and household detecting because it requires professionals to operate, is expensive, and is particularly hard to store the detecting agents.
Middle molecules (MM) (MW > 500 g/mol): P2-microglobulin, cytokines (interleukin 6), parathyroid hormon (PTH) - (at the same time belongs to the protein-bound group).
Protein-bound solutes: indoxyl sulfate, homocysteine, p-cresol, AGE products, hippuric acid.
Nowdays, due to availability of highly convective dialysis therapies like HemoDiaFiltration (HDF) which target to remove more efficiently the middle molecules (MM) (MW > 500 g/mol), the quality should be assessed by a marker molecule which belongs into MM uremic toxin group (e.g. p2-microglobulin), or behaves like MM as can be expected by several protein bounded uremic toxins. Lack of renal elimination of B2M in patients with end-stage kidney disease results in high level of serum concentrations and could attribute the cause of dialysis -related amyloidosis (Driieke TB, Massy ZA et al 2009) [15] and predict mortality in dialysis patients (Cheung AK, Rocco MV et al 2006 [12]; Cheung AK, Greene T et al 2008 [13]). Reduction of the accumulation and lower long-term levels of these compounds may prevent or delay the appearance of such complications and mortality. β2 -microglobulin (B2M) (MW 1 1 818 D) is the light chain of HLA class I complex and as such is expressed on all nucleated cells. B2M is normally found in low concentrations in the plasma. In end stage renal failure its concentration increases markedly secondary to reduced renal elimination. Uremia-related amyloid is to a large extent composed of B2M and is essentially found in the osteoarticular system and in the carpal tunnel. Uremia related amyloidosis becomes clinically apparent after several years of chronic renal failure and/or in the aged. B2M has become a frequently used marker for the dialytic removal of middle molecules. Behavior of B2M during dialysis is, however, not necessarily representative of that of other middle molecules. Hemodialysis with large pore membranes results in a progressive decrease of predialysis B2M concentrations and in a lower prevalence of dialysis-related amyloidosis and/or carpal tunnel syndrome. In a subanalysis of the
Hemodialysis (HEMO) Study, serum B2M levels were directly related to patient outcome. European Best Practice Guidelines (EBPG) have pointed out that despite no surrogate molecule has been identified yet with the characteristics of an ideal marker for MM uremic toxins, B2M is representative in its kinetic behaviour of other MM and peptides of similar size, and may be used as a marker for such molecules. (ERA-EDTA 2002) [16].
B2M is mainly determined by ELISA assay method. Although the method is automated as an automatic bio-analyzer, the merits of the ELISA itself reside in mass detecting discrepancy and complicacy of the method. It cannot be applied in routine or household detecting because it requires professionals to operate, is expensive, and there is hard to store the detecting agents. Great care has been taken to ensure the quality and reliability of the method but however, it is possible that in certain cases unusual results may be obtained due to high levels of interfering factors.
Many MM and protein bound uremic toxins are determined utilizing the high performance reverse liquid chromatography (HPLC) method. For example, indoxyl sulfate has been determined by fluorescence detection (excitation 280 nm, emission 340 nm), and hippuric acid has been analyzed by ultraviolet detection at 254 nm in the serum and in the spent dialysate (Dhondt, Vanholder et al. 2003) [14]. The demerits of this method include: 1) separation of the compounds may be difficult due to similar properties which affects the test accuracy; 2) the operation is complex, needs lots of agents and should be operated by professionals; 3) the sample needs pretreatment for deproteinization; and 4) the necessary equipment is expensive.
Another method for measuring concentration of a substance in a solution having an absorption at 300 nm or less is described in US20080304048A1. However, the method utilizes separation by chromatography which is not suitable for on-line monitoring of the uremic retention solutes.
Another method utilizing UV spectrometer aiming to measure the biocide, sanitizing solutions and quaternary ammonium cation is described in US7372039B2. However, the method utilizes specific wavelengths suitable only for abovementioned chemicals and not for uremic retention solutes in the biological fluids.
Another methods utilizing absorption spectra and spectrophotometric analysis in a liquid sample are described in US201 10040494 A 1 and EP1070954B1. However, the methods utilize library of the reference data as basis for the analysis which is not applicable for the for measuring and monitoring concentration of uremic retention solutes in a biological
fluid. Additionally, photo-oxidation of the sample is not valid for uremic retention solutes being an important step in EP1070954B1.
Another method for determination of the amount of waste products in the dialysis liquid during dialysis treatment to control the dialysis machine in order to adapt the dialysis treatment to the patient is described in US6666840, 23.12.2003, Falkvall et al, and in the reference (Fridolin, Magnusson et al. 2002) [17]. The measurements of a concentration of a certain substance or a combination of substances in the dialysis liquid are obtained continuously or regularly on a sample from outgoing dialysis liquid from a dialyzer during dialysis treatment. The measurements are performed spectrophotometrically by means of UV-radiation (wavelength in the range 180-380 nm). At least one parameter for the dialysis treatment is adjusted depending on the measurement of the concentration of the substance or combination thereof. The merits of the described method are that it does not need blood samples, no disposables or chemicals, and is fast. However, the described method is general and does not specify methodology to measure exclusively a single compound and is meant to apply only for dialysis monitoring. Moreover, no results about the concentration measurements are presented. More exact description about the uric acid and urea measurements using the abovementioned method is given in a scientific papers (Uhlin, Lindberg et al. 2005) [21], (Uhlin, Fridolin et al. 2005) [20]. Methods for determination of the dialysis dose as the Kt/V value during hemodialysis treatment using the slope of the natural logarithimic UV absorbance values vs time or the raw UV absorbance values are described earlier (Fridolin, Magnusson et al. 2002 [17]; Uhlin, Fridolin et al. 2003) [19], (Luman, Jerotskaja et al. 2009) [18]. Related method describing estimation of abovementioned parameters by recirculating the dialysis liquid against the blood flowing through the kidney substitution until an mass transfer equilibrium is obtained for both fluids enabling evaluate the initial blood waste concentration is described in EP2005982A1 , 20.06.2007, Castellarnau, A.
Another method relates to a method for dialysis monitoring method and apparatus using near infrared radiation, described in W09819592, 14.05.1998, RIO GRANDE MEDICAL TECH INC. The merits of the described method are similar to that of the UV-radiation. However, the described method measures urea and creatinine by utilizing near infrared radiation spectrometry with different technical and optical considerations. For near infrared radiation spectrometry the principial component analysis using calibration and prediction stage is described in US5886347.
Another method, described in RU2212029, 10.09.2003, VASILEVSKIJ A M et al, relies on the Beer-Lambert law and utilizes the millimolar extinction coefficients of the components in the spent dialysate. The example given in this invention describes concentration determination of urea, phosphate, creatinine and uric acid. However, the example is given only for one dialysis session which is a serious limitation and can not be applied for the general use. Furthermore, urea and phosphate do not absorb UV-radiation as incorrectly claimed in this application, and thus concentration measurement of urea and phosphate is impossible using this invention. Moreover, because of several unknown chromophores in the spent dialysate the concentration measurement of creatinine is not applicable using the Beer- Lambert law.
Thus, there is a need for a new method which can directly and easily monitor removal of uremic retention solutes during hemodialysis andperform quantitative concentration measurements of water soluble middle and small molecular weight uremic retention solutes in the biological fluids (e.g. in the spent dialysate) for estimation of nutritional status (protein nitrogen appearance and lean body mass) on dialysis patients and which avoids the disadvantages caused by the analysis in a laboratory.
Moreover, a parameter Lean Body Mass (LBM), suitable for automatic and time-efficient way to review the muscle mass and protein nutritional status of the HD patients, can be monitored by abovementioned novel method for quantitative concentration measurements of uremic retention solutes in the biological fluids.
Additionally, a new, simplified mapping of dialysis dose and nutrition is proposed by using only two parameters - Kt/V and nPNA, suitable for automatic and time-efficient way to review the performed HD strategy based on the data from on-line dialysate side dialysis monitors. The abovementioned novel method for quantitative concentration measurements of uremic retention solutes in the biological fluids combined with the new, simplified mapping of dialysis dose and nutrition, gives an added value for the real-time, automatic monitoring of dialysis patients.
Summary of the inventions
The purpose of the invention is, therefore, a new method and a device for measuring concentration of substances (e.g. middle molecular weight solutes - (MM) (MW > 500 g/mol): p2-microglobulin, Cytokines (Interleukin 6), Parathyroid hormon (PTH) - at the same time belongs to the protein-bound group, small molecular weight solutes - (MW < 500 g/mol): Urea, Creatinine, Uric acid, Guanidine -ADMA (asymmetric dimethylarginine), Phosphate) in biological fluids and monitoring removal of the said hardly and easily
diffusible uremic retention solutes during dialysis. More specifically, the present invention relates to an optical method utilizing optical spectrum of the biological fluids and UV- absorbance, preferable UV-absorbance of the spent dialysate or the peritoneal liquid, and concentration calculation algorithm containing the transforming function to determine on the samples or on-line the concentration of the substances, which can be effected directly at the bed-side, real-time and which avoids the disadvantages caused by the analysis in a laboratory. The method and device determines the concentration of the substances in-vitro or on-line utilizing a measuring cuvette (cell) suitable for specified measurements.
Another object of the present invention is to provide a novel and practical optical urea and creatinine measuring method and device which determines quantitatively concentration of the forementioned water soluble small molecular weight substances in the spent dialysate. Those concentration values can be represented directly and easily on the monitor or screen printed. The novel method and device does not require any chemical disposables, and can be easily made and mass-produced providing an environment-friendly optical method. Another object of the present invention is to provide a practical optical method and device determining quantitatively concentration or removal of the middle molecules and protein bound uremic toxins in the biological fluids. The determined values can be represented directly and easily on the monitor or screen printed. The method and device does not require any chemical disposables, neither expensive separation techniques, and can be easily made and mass-produced providing an environment-friendly optical method.
A still further object of the present invention is to provide a method for assessing routine clinical monitoring in order to face risks of higher mortality in patients (e.g. in dialysis). A still further object of the present invention is to provide a novel, rapid, convenient and safe method for detecting concentration of substances in a liquid sample. The liquid sample can be directly dropped on the detecting cuvette for in-vitro measurements or sent a flowing stream of fluid through a flow-through cell for on-line monitoring. The method is suitable for household use when being applied to detect the concentration of substances in the biological fluids.
The features and advantages described herein are not all-inclusive and, in particular, many additional features and advantages will be apparent to one of ordinary skill in the art in view of the drawings, specification, and claims. Moreover, it should be noted that the language used in the specification has been principally selected for readability and instructional purposed, and not to limit the scope of the inventive subject matter.
Brief description of the drawings
The present invention will be described below in the detailed description with reference to the accompanied drawings where:
Fig. 1 shows a block diagram of one embodiment of the invention.
Fig. 2 shows a block diagram of another embodiment of the invention applied for substances in a biological fluid during dialysis.
Urea
Fig. 3 shows the linear relationship between urea concentration measured by the known method (Predicted) and at the laboratory (Expected) for the "Calibration" group.
Fig. 4 shows the linear relationship between the urea concentration estimated by the new method (Predicted) and at the laboratory (Expected) for the "Calibration" group. The unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the water soluble small molecular weight substance urea was: Urea (t) [mmol/L] = 1.00 + 6.28* A(t, 295nm) - 8.86* A(t, 320nm) - 0.529* A(t, 253nm). Fig. 5 shows the linear relationship between the urea concentration estimated by the known method (Predicted) and at the laboratory (Expected) for the "Validation" group.
Fig. 6 shows the linear relationship between the urea concentration estimated by the new method (Predicted) and at the laboratory (Expected) for the "Validation" group.
Creatinine (Crea)
Fig. 7 shows the linear relationship between creatinine concentration measured by the known method (Predicted) and at the laboratory (Expected) for the "Calibration" group. Fig. 8 shows the linear relationship between creatinine concentration measured by the new method (Predicted) and at the laboratory (Expected) for the "Calibration" group. The unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the water soluble small molecular weight substance creatinine was: Crea (t) [mmol/L] = 31.7 + 231.2*A(t, 294nm) - 321.3* A(t, 314nm) -72.8* A(t, 283nm).
Fig. 9 shows the linear relationship between creatinine concentration estimated by the known method (Predicted) and at the laboratory (Expected) for the "Validation" group. Fig. 10 shows the linear relationship between creatinine concentration estimated by the new method (Predicted) and at the laboratory (Expected) for the "Validation" group.
Uric acid (UA)
Fig. 11 shows the linear relationship between the uric acid concentration measured by the known method (Predicted) and at the laboratory (Expected) for the "Calibration" group.
Fig. 12 shows the linear relationship between uric acid concentration measured by the new A method (Predicted) and at the laboratory (Expected) for the "Calibration" group. The unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the water soluble small molecular weight substance uric acid was: UA (t) [mmol/L] = - 3.896 + 86.51 *A(t, 298nm) - 91.21 * A(t, 312nm).
Fig. 13 shows the linear relationship between uric acid concentration measured by the new B method (Predicted) and at the laboratory (Expected) for the "Calibration" group. The unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the water soluble small molecular weight substance uric acid was: UA (t) [mmol/L] = -2.78 - 1169* A_d(t, 307nm) - 181.3 * A_d(t, 284nm).
Fig. 14 shows the linear relationship between the uric acid concentration estimated by the known method (Predicted) and at the laboratory (Expected) for the "Validation" group. Fig. 15 shows the linear relationship between the uric acid concentration estimated by the new A method (Predicted) and at the laboratory (Expected) for the "Validation" group. Fig. 16 shows the linear relationship between the uric acid concentration estimated by the new B method (Predicted) and at the laboratory (Expected) for the "Validation" group. Fig. 17 shows a new, simplified mapping of dialysis dose and nutrition applied by using only two parameters - Kt/V and nPNA, suitable for automatic and time-efficient way to review the performed HD strategy based on the data from on-line dialysate side dialysis monitor.
Fig. 18 shows an example to estimate a parameter Lean Body Mass (LBM), suitable for automatic and time-efficient way to review the muscle mass and protein nutritional status of the HD patients based on the data from on-line dialysate dialysis monitor as comparison between the known blood based (LBM b) and the novel UV-absorbance method (LBM_uv).
Fig. 19 shows the linear relationship expressed as the correlation coefficient r between Urea, Uric Acid (UA), and B2M concentration measured in the spent dialysate by the new method (by the UV absorbance) and at the laboratory for the total material (number of samples N = 72) over the wavelength range of 190 - 380 nm.
Fig. 20 shows the linear relationship between the B2M concentration in the spent dialysate estimated by the UV absorbance at 314 nm (Predicted) and at the laboratory (Expected) for the total material.
Fig. 21 shows a Bland- Altman plot of the estimated parameter eKt/V_B2M for 8 patients as the differences between eKt/Vb_B2M and eKt/Va_B2M (number of HDF sessions N = 20) plotted against mean_eKt/V (b&a)_B2M after bias correction.
Fig. 22 illustrates the dialysis dose for B2M as eKt/Va_B2M from the optical method measured in the spent dialysate plotted against eKt/Vb_B2M estimated using the blood samples (number of HDF sessions N = 20). A line of unity as a dashed line is also shown. Detailed description of the inventions
Fig. 1 shows a block diagram of one embodiment of the invention applied for determining content of the hardly or easily diffusible uremic retention solutes in the biological fluids. Another embodiment of the invention is shown in Fig. 2. The device is applied for determining the concentration of substances (uremic retention solutes) in a biological fluid during dialysis in spent dialysate 6. The device comprises spectrophotometer 7, a signal processing unit 8 for concentration calculation, a unit 9 for presenting concentration or treatment map 10 of the substance in the spent dialysate.
The block diagram of the device according to one embodiment of the invention is shown in Fig. 1. The device for measuring concentration of a hardly diffusible uremic retention solute 5 in a biological fluid 1 comprises:
an optical module 2, comprising a spectrophotometrical system, comprising a light source and a light detector;
a measuring cuvette for holding a sample of the biological fluid so that the light can be led through the sample;
a signal processing module 3 comprising a data acquisition module and a spectra processing module, and
a data representing module 4.
The light source can be either a broadband light source or a narrowband light source. If broadband light source is used, either a broadband detector with a filter can be used, or narrowband detectors. According to one embodiment, the optical module is operating in the ultra violet region (wavelength range 190-330 nm).
The measuring cuvette can be, e.g., adapted for in-vitro measurements, or designed for the on-line measurements.
According to one embodiment, the signal or spectra processing module is adapted to utilize the raw UV absorbance values or slope of the natural logarithimic UV absorbance values vs time to execute a dialysis dose calculation algorithm.
According to one embodiment, the signal or spectra processing module is adapted to utilize a unique set of optical spectral components at certain wavelengths, adapted to execute a concentration calculation algorithm comprising a transforming function calculating, preferable real-time, the concentration of the uremic retention solutes in the biological fluid. The transforming function, in order to transform UV-absorbance (dimensionless) into uremic retention solute concentration in mg/L or mmol/L, has the form
y = bO + bl *Al + b2*A2 + ... + bi*Ai + b(i+l)*xl + ...+ bn*xn,
where y is a dependent variable (i.e. uremic retention solute concentration in mg/L or mmol/L), bO is the intercept, bi-s are the appropriate regression coefficients, Al - Ai-s are the measured UV-absorbances at the certain wavelengths, and xi-s are other appropriate variables.
The data representing module is adapted to execute a program for data representation and comprises or is connected to a data visualization module, e.g., a monitor, a display, or a printing device.
The data visualization module is adapted for a new, simplified mapping of dialysis dose and nutrition is applied by using only two parameters - Kt V and nPNA, suitable for automatic and time-efficient way to review the performed HD strategy based on the data from on-line dialysate side dialysis monitors.
Examples
Example 1 Concentration measurements of urea, creatinine and uric acid, in the spent dialysate
Concentration measurements of certain easily diffusible uremic retention solutes, urea, creatinine and uric acid, in the spent dialysate is given as an example of the present invention.
Subjects: A group of uremic patients on chronic thrice-weekly hemodialysis were included in the study at the Department of Dialysis and Nephrology. The dialysate flow was 500 mL/min and the blood flow varied between 245 to 350 mL/min. The type of dialysis machine used was Fresenius 4008H (Fresenius Medical Care, Germany).
Methods: The optical module consisted of a double-beam spectrophotometer (SHIMATSU UV-2401 PC, Japan) with an accuracy of ±1% on the dialysate samples taken at predetermined times during dialysis. Spectrophotometric analysis over a wavelength range of 190 - 380 nm was performed by a cuvette with an optical path length of 1 cm. The data acquisition module consisted of a PC incorporated in the spectrophotometer using UV-PC software (UV-PC personal spectrophotometer software, version 3.9 for Windows). The
obtained UV-absorbance values were processed and presented by a signal processing module using a known (uniwavelength) algorithm, and the novel (multiwavelength) algorithm by a specially developed application by a concentration calculation algorithm containing the transforming function calculating the concentration of certain substance in the biological fluid. The data representing module was either the computer screen or a printer.
The dialysate samples were taken during the dialysis. Pure dialysate was collected before the start of a dialysis session, used as the reference solution, when the dialysis machine was prepared for starting and the conductivity was stable.
The concentrations of the substances such as urea, creatinine and uric acid, were determined at the clinical chemistry laboratory using standardized methods. On the basis of the results the determination coefficient R2, systematic error (BIAS) and standard error (SE) were calculated for the known and new method using concentrations from the laboratory as the reference as:
N
∑«,
BIAS = -^—
where e,- is the i-th residual and N is the number of observations. The i-th residual was obtained as the difference between laboratory and optically determined parameter values for the i-th measurement.
The results (see Results) obtained by the closest existing method for determination of the amount of waste products in the dialysis liquid during dialysis treatment described in W09962574, US6666840B1 is referred here as the„known method". Those results are compared to the results by the method subject to this invention noted as the„new method". The linear relationship between urea, creatinine and uric acid concentrations, measured by the known and new method (Predicted) and at the laboratory (Expected), was first assessed using only a part of the data material, called as the "Calibration" group. After creating a model for the "Calibration" group the obtained model was applied on the rest of the material, called as the "Validation" group, not included into the model build up.
Including new patients should be the most sensitive because of the possible different combination or composition of the UV-absorbing compounds filtered from the blood into
the dialysate during the dialysis may influence the model accuracy. To test a such situation only a part of the patients were included into the "Calibration" group to create a model, and after that new patients not presented before were included into the "Validation" group to validate the model.
Results
Fig. 3 and Fig. 4 show the linear relationship between urea concentration measured by the known and new method (Predicted) and at the laboratory (Expected) for the "Calibration" group.
The new method utilises an unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the water soluble small molecular weight substance urea obtained by building up the model on the "Calibration" group. The transforming function, in order to transform UV-absorbance (dimensionless) into urea concentration [mmol/L], has the form
Urea (t) [mmol/L] = 1.00 + 6.28* A(t, 295nm) - 8.86* A(t, 320nm) - 0.529* A(t, 253nm) where Urea (t) [mmol/L] is a dependent variable urea concentration in mmol/L at the time moment t, A(t, λί nm) are the measured variables, i.e. absorbances at certain wavelengths at the time moment t multiplied by the appropriate coefficients.
Fig. 5 and Fig. 6 show the linear relationship between urea concentration measured by the known and new method (Predicted Urea) and at the laboratory (Expected Urea) for the "Validation" group including the material not included into the model build up.
Fig. 7 and Fig. 8 show the linear relationship between creatinine concentration measured by the known and new method (Predicted Crea) and at the laboratory (Expected Crea) for the "Calibration" group. The R2 is increased remarkably compared to the known method.
The new method utilises an unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the water soluble small molecular weight substance creatinine obtained by building up the model on the "Calibration" group. The transforming function, in order to transform UV-absorbance (dimensionless) into creatinine concentration [mmol/L], has the form
Crea (t) [mmol/L] = 31.7 + 231.2*A(t, 294nm) - 321.3* A(t, 314nm) -72.8* A(t, 283nm) where Crea (t) [mmol/L] is a dependent variable creatinine concentration in mmol/L), at the time moment t, A(t, λί nm) are the measured variables, i.e. absorbances at certain wavelengths at the time moment t multiplied by the appropriate coefficients.
Fig. 9 and Fig. 10 show the linear relationship between creatinine concentration estimated by the known and new method (Predicted Crea) and at the laboratory (Expected Crea) for
the "Validation" group. The R2 is increased remarkably utilizing the new method compared to the known method even for the "Validation" group including the material not included into the model build up.
Fig. 1 1 show the linear relationship between uric acid concentration estimated by the known method (Predicted) and at the laboratory (Expected) for the "Calibration" group. Fig. 12 and Fig. 13 show the linear relationship between uric acid concentration estimated by the new methods (A and B) (Predicted) and at the laboratory (Expected) for the "Calibration" group. The R2 is increased utilizing the new method compared to the known method even for the "Calibration" group.
The new method A utilises an unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the water soluble small molecular weight substance uric acid obtained by utilizing measured UV-absorbance values, and building up the model on the "Calibration" group. The transforming function of this method, called as "New A method", in order to transform UV-absorbance (dimensionless) into uric acid concentration [mmol/L], has the form
UA (t) [mmol/L] = - 3.896 + 86.51 *A(t, 298nm) - 91.21 * A(t, 312nm)
where UA (t) [mmol/L] is a dependent variable uric acid concentration in mmol/L at the time moment t, A(t, λί nm) are the measured variables, i.e. absorbances at certain wavelengths at the time moment t multiplied by the appropriate coefficients.
Additionally, the new method B utilises an unique set of optical spectral components at certain wavelengths, to determine, preferable on-line, the concentration of the water soluble small molecular weight substance uric acid obtained by utilizing the processed UV- absorbance values by Sawitsky-Golay method, and building up the model on the "Calibration" group. The transforming function of this method, called as "New B method", in order to transform UV-absorbance (dimensionless) into uric acid concentration [mmol/L], has the form
UA (t) [mmol/L] = -2.78 - 1 169* A_d(t, 307nm) - 181.3* A_d(t, 284nm)
where UA (t) [mmol/L] is a dependent variable uric acid concentration in mmol/L at the time moment t, A_d(t, λί nm) are the variables (measured and the processed UV-absorbance values by Sawitsky-Golay method), i.e. processed absorbances at certain wavelengths at the time moment t multiplied by the appropriate coefficients.
Fig. 14 show the linear relationship between uric acid concentration estimated by the known method (Predicted) and at the laboratory (Expected) for the "Validation" group. Fig. 15 and Fig. 16 show the linear relationship between uric acid concentration estimated by the
new methods (A and B) (Predicted) and at the laboratory (Expected) for the "Validation" group. The R2 is increased remarkably utilizing the new method compared to the known method even for the "Validation" group including the material not included into the model build up.
As seen from the Tables 1-3 determination of urea, creatinine and uric acid concentrations can be done much more precisely applying the "New method". The R is increased, and validation SE is decreased compared to the "Known method".
Table 3: Summary results for the different methods to measure concentration of the acid.
This means that utilizing the new methods the concentrations of urea, creatinine and uric acid can be predicted more accurately in terms of BIAS and SE.
Fig. 17 shows a new, simplified mapping of dialysis dose and nutrition applied by using only two parameters - Kt/V and nPNA, suitable for automatic and time-efficient way to review the performed HD strategy based on the data from on-line dialysate side dialysis monitor, utilizing the urea concentration determination method described above.
Fig. 18 shows an example to estimate a parameter Lean Body Mass (LBM), suitable for automatic and time-efficient way to review the muscle mass and protein nutritional status of the HD patients based on the data from on-line dialysate dialysis monitor as comparison between the known blood based (LBM b) and the novel UV-absorbance method (LBM_uv), utilizing the creatinine concentration determination method described above. Although this invention is described with respect to a set of aspects and embodiments, modifications thereto will be apparent to those skilled in the art. The foregoing description of the embodiments of the invention has been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Many modifications and variations are possible in light of this disclosure. It is intended that the scope of the invention be limited not by this detailed description, but rather by the claims appended hereto.
Example 2 Concentration measurement of a hardly diffusible middle molecule beta2- microglobulin (B2M)
Concentration measurement of a certain hardly diffusible uremic retention solute, a middle molecule beta2-microglobulin (B2M), in the spent dialysate, is given as an example of the present invention.
Subjects: Eight uremic patients, one female and seven males, were included in the study. All patients were on chronic three -weekly on-line HemoDiaFiltration (ol-HDF) at the Department of Nephrology, University Hospital of Linkoping, Sweden. The dialysis machine used was a Fresenius 5008 (Fresenius Medical Care, Germany). The dialyzers used were in all treatments FX 800 (Fresenius Medical Care, Germany), with an effective membrane area of 1.8 m2, with an ultra filtration coefficient of 63 ml/h mmHg. The duration of the ol-HDF treatments varied between 180 to 270 minutes, the dialysate flow was 500 mL/min, the blood flow varied between 280-350 mL/min. All patients were dialyzed via artery-venous fistulas using a "two-needle" system. The auto sub system mode for calculation of the on-line prepared substitution volume varied between 12.2 to 29.7 liters per session.
Sampling: Samples from the drain tube were taken at (min) 9 and at the end of ol-HDF session. One sample was taken from the dialysate/ultrafiltrate collection tank after careful stirring and weighing was performed. If a self-test of the dialysis machine occurred during the planned sampling time, the sample was taken when the UV-absorbance curve reached baseline level again which occurred within 2-3 minutes. Pure dialysate was collected before
the start of a dialysis session, used as the reference solution, when the dialysis machine was prepared for starting and the conductivity was stable.
Determination of concentrations of B2M in the spent dialysate/ultrafiltrate was performed at the Chemical Laboratory, University Hospital in Linkoping.
Results: Fig. 19 illustrates the examples of shows the linear relationship expressed as the correlation coefficient r between Urea, Uric Acid (UA), and B2M concentrations measured in the spent dialysate by the new method (by the UV absorbance) and at the laboratory for the total material (number of samples N = 72) over the wavelength range of 190 - 400 nm. Some distinctive correlation maxima at specific regions for different uremic solutes are clearly seen. The linear relationship analysis for B2M, utilizing UV absorbance values at the wavelength which yielded the strongest correlation (314 nm) and the concentrations from the laboratory. This led to a specific model which enabled transform the optical measurements into the B2M concentration values. The function, in order to transform UV-absorbance (dimensionless) into the B2M concentration in mg/L, had the form:
B2M (t) [mg/L] = 8.13* A(t, 314 nm).
The determined values of B2M concentrations in the spent dialysate by the the new method, obtained by the specific model utilizing the UV absorbance at 314 nm (Predicted B2M) have strong linear relationship between the B2M concentrations estimated at the laboratory (Expected B2M) for the total material (Fig 20).
Table 4 summarises all results about the B2M concentrations as mean and standard deviation values (Mean +/- SD) from the standardised methods (Lab) and from the new method (UV). The linear correlation coefficient (r) and the R-squared value (R ) between the B2M concentration from the optical method and concentration measured at the laboratory, the accuracy (BIAS) and precision (SE) for the different methods to measure concentration of B2M, are also given.
Table 4: Summary results about the concentration mean and standard deviation values (Mean +/- SD) from the standardised methods (Lab) and new method (UV), linear correlation coefficient (r) and the R-squared value (R ) between the uremic toxins concentration from the optical method and concentration measured at the laboratory, the accuracy (BIAS) and precision (SE) for the different methods to measure concentration of
B2M.
SE rmg/Ll 0.37
As seen from the Table 4 determination of B2M concentration can be done with satisfactory accuracy and precision applying the novel method.
As an example for clinical application, the removal of B2M from the optical measurements is estimated below to calculate the dialysis dose for B2M, being representative in its kinetic behavior of other MM and peptides of similar size.
The dialysis dose for the B2M from blood, spKt/Vb_B2M and eKt/Vb_B2M, can be calculated using the pre- and post- dialysis blood B2M concentrations (C0 and Ct). The single pool volume Kt/V, spKt/Vb_B2M was calculated according to the formula proposed by Casino et al 2010 [1 1], as
where UF is the total ultrafiltration in kg and W is the patient's dry body weight in kg. The equilibrated Kt/V, eKt/Vb_B2M, taking account post-dialysis B2M rebound, was obtained according to the formula proposed by Tattersall et al 2007, as:
eKt/Vb _ B2M = spKt/Vp2m * Td /(Td + 11 θ) (4 where Td is the dialysis session length.
For determination of the dialysis dose for B2M from the optical method, instead of the pre- and post-dialysis blood B2M concentrations, the UV-absorbance value in the beginning, A0 (9 min dialysate sample) and at the end of dialysis, At , were utilized at the wavelength which yielded the strongest correlation between B2M concentrations measured in the spent dialysate by the new method (by the UV absorbance) and at the laboratory (314 nm). The single pool volume Kt/V from the absorbance measurements, spKt/V a_B2M was calculated as
The equilibrated Kt/V from the absorbance measurements, eKt/Va_B2M was calculated according to equation 4.
Table 5 summarises all results about the dialysis dose for the B2M as eKt/V_B2M calculated using the pre- and post- dialysis blood B2M concentrations and the absorbance values from totally 20 HDF sessions. The linear correlation coefficient (r) and the R-squared value (R2) between the dialysis dose for B2M from the optical method and dialysis dose for B2M from the blood concentrations are given. The accuracy (BIAS) and precision (SE) for the optical method was calculated using dialysis dose for the B2M from blood as reference after bias correction.
Table 5: Summary of dialysis dose as eKt/V_B2M, calculated by the TDC and the absorbance values on the tank dialysate sample (UV) , the linear correlation coefficient (r) and the R-squared value (R ) between the dialysis dose for B2M from the optical method and from the blood concentrations, the accuracy (BIAS) and precision (SE) for the optical method.
Fig. 21 presents a comparison as a Bland- Altaian plot of the estimated parameter eKt/V_B2M for all 8 patients as the differences between eKt/Vb_B2M and eKt Va_B2M (number of HDF sessions N = 20) plotted against mean_eKt/V(b&a)_B2M after bias correction. Fig. 22 illustrates the dialysis dose for B2M as eKt/Va_B2M from the optical method measured in the spent dialysate plotted against eKt/Vb_B2M estimated using the blood samples (number of HDF sessions N = 20). A line of unity as a dashed line is also shown.
The results show good agreement between the dialysis dose estimated for B2M from the blood samples and from the spent dialysate samples by the UV-absorbance.
As the third example for clinical application, the concentration of B2M from optical measurements is utilized below to calculate the total removed B2M, TR_B2M.
The TR B2M from TDC (reference) was calculated as B2M concentration in the tank at the end of dialysis multiplied by collected weight [kg], assuming that 1kg = 1L of the dialysate.
Similarly, TR B2M from the UV-absorbance was calculated as B2M concentration in the tank at the end of dialysis estimated by UV-absorbance utilising the transforming function, and multiplied by collected weight [kg], assuming that lkg = 1L of the dialysate.
Table 6 summarises all results about the dialysis dose for the B2M as the total removed B2M, TR_B2M, calculated using the B2M concentrations in the tank at the end of dialysis estimated at the laboratory (TDC), and by the UV-absorbance (UV) from totally 20 HDF sessions. The linear correlation coefficient (r) and the R-squared value (R2) between the dialysis dose for B2M from the optical method and dialysis dose for B2M from the blood concentrations are given. The accuracy (BIAS) and precision (SE) for the optical method was calculated using dialysis dose for the B2M from blood as reference after bias correction.
Table 6: Summary of dialysis dose as TR B2M, calculated using using the B2M concentrations in the tank at the end of dialysis estimated at the laboratory (TDC) and by the UV-absorbance (UV), the linear correlation coefficient (r) and the R-squared value (R2) between the dialysis dose for B2M from the optical method and from the blood concentrations, the accuracy (BIAS) and precision (SE) for the optical method.
As seen from the Table 6 determination of TR B2M can be done with satisfactory accuracy and precision applying the novel method.
Although this invention is described with respect to a set of aspects and embodiments, modifications thereto will be apparent to those skilled in the art. The foregoing description of the embodiments of the invention has been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Many modifications and variations are possible in light of this disclosure. It is intended that the scope of the invention be limited not by this detailed description, but rather by the claims appended hereto.
Patent references:
US5357960, Method and apparatus for the quantitative determination of optically active substances, SCHMIDTKE G et al
US2007023334, An apparatus, a system and a method relating to hemodialysis,
hemodiafiltration, hemofiltration or peritoneal dialysis. HALLSTADIUS H, BERTINSSIN G I
US6121050, Analyte detection systems, HAN CHI-NENG A
US20080304048A1, Methods and apparatus for measuring the concentration of a substance in a solution, TORMOD S
US7372039B2, Near UV absorption spectrometer and method for using the same,
TOKHTUEV E et al.
US20110040494 Al, Method and apparatus for absorption spectra analysis, FOSTER KA EP1070954B1 , Method and device for analysis of a liquid sample, SECOMAM
US6666840, Method for determining waste products in the dialysis liquid in dialysis treatment, FALKVALL T et al
W09819592, Dialysis monitoring method and apparatus, KEMENY G J, MAYNARD J D US5886347, Analytical method for multi-component aqueous solutions and apparatus for the same, INOUE M.
RU212029 CI,„Way of analysis of liquid biological medium in process monitoring", VASILEVS IJ A M et al
WO2009071 102, Ivo Fridolin, Jana Jerotskaja, Kai Lauri and Merike Luman. Optical method and device for measuring concentrations of substances in biological fluids.
04.12.2007.
EP2005982A1 Castellarnau, A. Method for determining the reduction ratio or the Kt/V value of a kidney substitution treatment and apparatus for the realization of the method B.Braun Avitum AG Date of filing: 20.06.2007
Non-patent references:
[1] Yavuz, A., et al. (2005). "Uremic toxins: a new focus on an old subject." Semin Dial (May-Jun; 18(3)): 203-1 1.
[2] Artiss, J. D., R. E. Karcher, et al. (2000). "Application and evaluation of a new cold- stable kinetic Jaffe reagent to the Hitachi 747 for the determination of serum creatinine." Microchemical Journal 65(3): 277-282.
[3] Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle (review). Nutr Metab (Lond) 2004 Oct 19;1(1):10
[4] Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008 Oct 23;359(17): 181 1-21. Review.
[5] Viazzi F, Leoncini G, Ratto E, Pontremoli R. Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived. J Clin Hypertens 2006;
8(7):510-518
[6] Hoieggen A, Alderman MH, Kjeldsen SE et al; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004 Mar;65(3):1041- 9
[7] Nakagawa T, Mazzali M, Kang D-H, Sanchez-Lozada LG, Herrera-Acosta J, Johnson RJ. Uric acid- a uremic toxin? Blood Purif. 2006; 24:67-70
[8] De Smet R, Glorieux G, Hsu C, Vanholder R. P-cresol and uric acid: two old uremic toxins revisited. Kidney Int 1997, Nov;62:S8-l 1
[9] Perlstein T S, Gumieniak O, Hopkins P, Murphey L, Brown N, Williams G, et. al. Uric acid and the state of intrarenal renin-angiotensin system in humans. Kidney Int 2004;
66: 1465-1470.
[10] Navaneethan SD, Beddhu S. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transplant. 2009 Apr;24(4): 1260-66.
[11] Casino FG, Pedrini LA, Santoro A, Mandolfo S, David S, De Cristofaro V, Teatini U, Lomonte C, Lopez T.A simple approach for assessing equilibrated Kt/V beta 2-M on a routine basis. Nephrol Dial Transplant. 2010 Sep;25(9):3038-44
[12] Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G. Serum -2 microglobulin levels predict mortality in dialysis patients: results of the HEMO Study. J Am Soc Nephrol 2006 Feb;17(2):546-55
[13] Cheung AK, Greene T, Leypoldt JK, Yan G, Allon M, Delmez J, Levey AS, Levin NW, Rocco MV, Schulman G, Eknoyan G; HEMO Study Group. Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2008 Jan;3(l):69-77.
[14] Dhondt, A. W., R. C. Vanholder, et al. (2003). "Studies on dialysate mixing in the Genius (R) single-pass batch system for hemodialysis therapy." Kidney International 63(4): 1540-1547.
[15] Driieke TB, Massy ZA. Beta2-microglobulin. Semin Dial. 2009 Jul-Aug;22(4):378-80. Review
[16] ERA-EDTA (2002). "EBPG - European Best Practice Guidelines: SECTION II.
Haemodialysis adequacy II.2 Haemodialysis dose quantification: middle molecules (MM)." Nephrology Dialysis Transplantation 17 [Suppl 7]: 21-23.
[17] Fridolin, I., M. Magnusson, et al. (2002). "On-line monitoring of solutes in dialysate using absorption of ultraviolet radiation: technique description." The International Journal of Artificial Organs 25(8): 748-761.
[18] Luman, M., J. Jerotskaja, et al. (2009). "Dialysis dose and nutrition assessment by optical on-line dialysis adequacy monitor." Clinical Nephrology 72(4): 303-31 1.
[19] Uhlin, F., I. Fridolin, et al. (2003). "Estimation of delivered dialysis dose by on-line monitoring of the UV-absorbance in the spent dialysate." American Journal of Kidney Diseases 41(5 (May)): 1026-1036.
[20] Uhlin, F., I. Fridolin, et al. (2005). "Estimating total urea removal and protein catabolic rate by monitoring UV absorbance in spent dialysate." Nephrol Dial Transplant. Nov.
20(( 1 1)): 2458-2464.
[21] Uhlin, F., L. G. Lindberg, et al. (2005). Total Removed Uric Acid During Dialysis Estimated by On-line Ultra Violet Absorbance in the Spent Dialysate. 3rd European Medical & Biological Engineering Conference, EMBEC'05, Prague, Czech Republic, IFMBE Proceedings 1 1, CD-ISSN: 1727-1983, 6 pages, IFMBE Proceedings.
[22] Vanholder, R., R. De Smet, et al. (2003). "Review on uremic toxins: classification, concentration, and interindividual variability." Kidney International 63(5): 1934-1943.
Claims
1. A method for measuring and monitoring concentration of substances in a biological fluid, the method comprising the following subsequent steps of:
a) introducing the sample or flowing stream of the biological fluid into a cuvette; b) applying light from light source with predetermined wavelengths to the sample of the biological fluid and recording an optical spectrum of said sample by the light detector;
c) using the transforming function including a unique set of optical spectral components at certain wavelengths for calculating, preferable in real-time, the concentration of the substances in said biological fluid.
2. The method as in claim 1 , wherein after step c) the raw UV absorbance values or slope of the natural logarithmic UV absorbance values versus time are used to execute a dialysis dose calculation algorithm.
3. The method as in claim 1, wherein flowing stream of the biological fluid is introduced through flow-cuvette.
4. The method as in claim 1 , wherein substances in a biological fluid are hardly or easily diffusible uremic retention solutes.
5. The method as in claim 4, wherein the hardly diffusible uremic retention solute is beta2- microglobulin.
6. The method as in claim 4, wherein the easily diffusible uremic retention solutes are urea, creatinine or uric acid.
7. The method as in claim 1 , wherein the biological fluid comprising said substance is exposed in the cuvette to the wavelength induced by the light source in the ultra violet region.
8. The method as in claim 7, wherein the biological fluid comprising said substance is exposed to the wavelength induced by the light source from 180-400 nm.
9. The method as in claim 7, wherein the light source and the light detector are operating in the wavelength range 300-330 nm, suitable for beta2-microglobulin measurements.
10. The method as in claim 7, wherein the light source and the light detector are operating in the wavelength range 180-310 nm, suitable for urea, creatinine or uric acid.
11. The method as in claim 1, wherein the calculating the concentration of the substances in a biological fluid comprises executing a transforming function according to the formula y = bO + bl *xl + b2*x2 + b3*x3 + ...+ bn*xn, where y is a concentration of the substance in a biological fluid in mmol/L, xi-s are the measured absorbances or other important parameters in the wavelengths range 180-400 nm, and bi-s are the appropriate coefficients.
12. The method as in claim 2, wherein the signal dialysis dose calculation algorithm utilises directly raw UV- absorbance values or slope of the natural logarithimic UV absorbance values vs time.
13. The method as in claim 1 , wherein the sample of the biological fluid comprising said substances is dropped onto in- vitro cuvette.
14. The method as in claim 1, wherein the sample of the biological fluid comprising said substances is obtained and introduced into cuvette in home conditions.
15. The method as in claim 1, wherein the concentrations of the substances in a biological fluid are outputted to a display device or to a printer.
16. A method of monitoring of a patient by monitoring removal of the substances in a biological fluid during dialysis and by measuring concentration of said substances in patient's biological fluid, comprising:
a) introducing a flow of patients biological fluid into flow-cuvette;
b) applying light with predetermined wavelengths to the sample and recording an optical spectrum of the sample;
c) using the transforming function including a unique set of optical spectral components at certain wavelengths for calculating, preferably in real-time, the concentration of the substances in a biological fluid in the sample from the patient's biological fluid.
17. The method as in claim 16, wherein the concentration data measured during the monitoring of said substance are recorded and stored in a memory device.
18. The method as in claim 16, comprising visualization module adapted for a novel mapping of dialysis dose and nutrition by using only two parameters - Kt/V and nPNA for urea, suitable for automatic and time-efficient way to review the performed HD strategy based on the data from on-line dialysate side dialysis monitors.
19. The method as in claim 16, comprising calculation of a parameter Lean Body Mass (LBM) for creatinin, suitable for automatic and time-efficient way to review the muscle mass and protein nutritional status of the HD patients based on the said substance concentration determination method.
20. The method as in claim 16, comprising a comparisation of the substance concentration level in the biological fluid with predetermined limits of the concentration and generating an alarm signal, if the concentration does not fall between predetermined limits.
21. A device for measuring and monitoring concentration of substances or for monitoring removal of substances in a biological fluid utilizing UV-absorbance measurements during dialysis, the device comprising:
- a measuring cuvette for holding a sample or passing through the biological fluid; - an optical module comprising a spectrophotometrical system, comprising a light source for introducing light into the sample, and a light detector for receiving light from the sample;
- a signal processing module comprising a data acquisition module, a spectra processing module and a data representing module, the data representing module adapted to execute a program for data representation and comprising a data visualization module.
22. The device as in claim 21 wherein the substances in a biological fluid introduced into a measuring cuvette are hardly or easily diffusible uremic retention solutes.
23. The device as in claim 21, the light source and the light detector are operating in wavelength range 180-400 ran.
24. The device as in claim 23, the light source and the light detector are operating in the wavelength range 300-330 nm, suitable for beta2-microglobulin measurements.
25. The device as in claim 21 , wherein the light source is a broadband light source.
26. The device as in claim 21 , wherein the optical module comprises a filter and a broadband detector.
27. The device as in claim 21, wherein the optical module comprises narrowband detectors.
28. The device as in claim 21, wherein the optical module comprises a set of narrowband light sources and a broadband detector.
29. The device as in claim 21, wherein the cuvette is a flow-cuvette for receiving a flowing stream of the spent dialysate.
30. The device as in claim 29, wherein the cuvette is adapted for in-vitro measurements.
31. The device as in claim 21, wherein the signal processing module is adapted to execute a concentration calculation algorithm containing the transforming function calculating the concentration of substances in the biological fluid according to the formula y = bO + bl *xl + b2*x2 + b3*x3 + ...+ bn*xn, where y is a hardly or easily diffusible uremic retention solute concentration in mmol/L, xi-s are the measured absorbances or other important parameters in the wavelengths range 190-400 nm, and bi-s are the appropriate coefficients.
32. The device as in claim 21, wherein the signal processing module is adapted to execute a concentration calculation algorithm containing the transforming function, including a unique set of optical spectral components at certain wavelengths, whereas the transforming function, in order to transform UV-absorbance (dimensionless) into the concentration of a substance in a biological fluid [mmol/L], has the formula y = bO + bl *xl + b2*x2 + b3*x3 + ...+ bn*xn, where y is the solute concentration in mmol/L, xi-s are the measured absorbances or other important parameters, and bi-s are the appropriate coefficients.
33. The device as in claim 21, wherein the signal processing module is adapted to execute a dialysis dose calculation algorithm utilizing directly raw UV- absorbance values or slope of the natural logarithimic UV absorbance values vs time.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EEP201000049A EE05674B1 (en) | 2010-05-27 | 2010-05-27 | Apparatus and method for the quantitative determination of urea, creatinine and uric acid in water soluble substances of low molecular weight |
EEP201100002A EE05637B1 (en) | 2011-01-14 | 2011-01-14 | Method and apparatus for measuring concentrations of diffusible uremic retention solutes in biological fluid and monitoring their removal in UV-absorbed renal replacement therapy |
PCT/EE2011/000005 WO2011147425A1 (en) | 2010-05-27 | 2011-05-27 | Method and device for measuring and monitoring concentration of substances in a biological fluid |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2577270A1 true EP2577270A1 (en) | 2013-04-10 |
Family
ID=44484872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20110741089 Withdrawn EP2577270A1 (en) | 2010-05-27 | 2011-05-27 | Method and device for measuring and monitoring concentration of substances in a biological fluid |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2577270A1 (en) |
WO (1) | WO2011147425A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011101193A1 (en) | 2011-05-11 | 2012-11-15 | Ldiamon As | Method and detection device for determining the uric acid and creatinine content |
RU2499557C1 (en) * | 2012-10-08 | 2013-11-27 | Арсений Юрьевич Шитов | Method of estimating volume-regulating function of kidneys in conditions of higher pressure of gaseous medium |
DE102012112790A1 (en) * | 2012-12-20 | 2014-06-26 | B. Braun Avitum Ag | Method and device for the determination of waste products such as indoxyl sulfates in dialysis |
RU2525738C1 (en) * | 2013-04-09 | 2014-08-20 | Арсений Юрьевич Шитов | Method for evaluation of calcium-urethric human kidney function under conditions of increased pressure of gas medium |
DE102014106489A1 (en) * | 2014-05-08 | 2015-11-12 | B. Braun Avitum Ag | Device and device control method for the quantitative determination of the concentration of selected substances filtered out of a patient's body in a liquid |
CN105823746B (en) * | 2016-05-23 | 2018-08-17 | 青岛海大生物集团有限公司 | The detection method of chitosan content in a kind of water-soluble fertilizer |
US11255844B2 (en) | 2018-03-06 | 2022-02-22 | Fresenius Medical Care Holdings, Inc. | Peritoneal dialysis systems and related methods |
EP3939050A1 (en) | 2019-03-11 | 2022-01-19 | Gambro Lundia AB | Estimating generation rate of substance in dialysis patients |
RU2709469C1 (en) * | 2019-10-03 | 2019-12-18 | Арсений Юрьевич Шитов | Method of determining degree of individual resistance of divers to toxic effect of nitrogen on indicators of renal functions |
RU2709477C1 (en) * | 2019-10-03 | 2019-12-18 | Арсений Юрьевич Шитов | Method of determining degree of individual resistance of divers to toxic action of oxygen on indicators of renal functions |
EP4291891A1 (en) * | 2021-02-12 | 2023-12-20 | Ausmed Global Ltd | A system and method for determining a concentration of an analyte in a fluid |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010034626A1 (en) * | 2010-08-17 | 2012-02-23 | B. Braun Avitum Ag | Device for extracorporeal blood treatment |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3908114C1 (en) | 1988-10-07 | 1990-02-15 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De | |
JP3261264B2 (en) | 1994-07-13 | 2002-02-25 | 株式会社堀場製作所 | Multicomponent aqueous solution analysis method and analyzer |
WO1998019592A1 (en) | 1996-11-01 | 1998-05-14 | Rio Grande Medical Technologies, Inc. | Dialysis monitoring method and apparatus |
US6121050A (en) | 1997-08-29 | 2000-09-19 | Han; Chi-Neng Arthur | Analyte detection systems |
SE525639C2 (en) | 1998-06-04 | 2005-03-22 | Thore Falkvall | Determination of slag products in dialysis fluid by means of optical sensor |
FR2796722B1 (en) | 1999-07-20 | 2001-09-14 | Secomam Sa | METHOD AND DEVICE FOR DIGITIZATION, ARCHIVING, CHARACTERIZATION AND ANALYSIS OF A LIQUID SAMPLE |
RU2212029C1 (en) | 2001-12-03 | 2003-09-10 | Общество с ограниченной ответственностью "Клиника экстракорпоральной гемокоррекции" | Way of analysis of liquid biological medium in process of monitoring |
US7002670B2 (en) * | 2002-06-12 | 2006-02-21 | Baxter International Inc. | Optical sensor and method for measuring concentration of a chemical constituent using its intrinsic optical absorbance |
US20070023334A1 (en) | 2003-09-23 | 2007-02-01 | Gambro Lundia Ab | Apparatus, a system and a method relating to hemodialysis, hemodiafiltration, hemofiltration or peritoneal dialysis |
GB0524225D0 (en) | 2005-11-29 | 2006-01-04 | Amersham Biosciences Ab | Methods and apparatus for detecting and measuring the concentration of a substance in a solution |
US7372039B2 (en) | 2005-12-20 | 2008-05-13 | Ecolab Inc. | Near UV absorption spectrometer and method for using the same |
DE602007008544D1 (en) | 2007-06-20 | 2010-09-30 | Braun B Avitum Ag | Device for determining the reduction ratio or the Kt / V ratio of renal replacement therapy |
US8847163B2 (en) | 2007-11-26 | 2014-09-30 | Evoqua Water Technologies Llc | Method and apparatus for absorption spectra analysis |
WO2009071102A1 (en) | 2007-12-04 | 2009-06-11 | Tallinn University Of Technology | Optical method and device for measuring concentrations of substances in biological fluids |
-
2011
- 2011-05-27 WO PCT/EE2011/000005 patent/WO2011147425A1/en active Application Filing
- 2011-05-27 EP EP20110741089 patent/EP2577270A1/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010034626A1 (en) * | 2010-08-17 | 2012-02-23 | B. Braun Avitum Ag | Device for extracorporeal blood treatment |
EP2605810A1 (en) * | 2010-08-17 | 2013-06-26 | B. Braun Avitum AG | Apparatus for extracorporeal blood treatment |
Non-Patent Citations (1)
Title |
---|
See also references of WO2011147425A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011147425A1 (en) | 2011-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011147425A1 (en) | Method and device for measuring and monitoring concentration of substances in a biological fluid | |
US20230243752A1 (en) | System and method for monitoring the health of dialysis patients | |
JP4515786B2 (en) | Method for reducing the influence of hematocrit on the measurement of an analyte in whole blood, and a test kit and a test article useful in the method | |
AU2012241983B2 (en) | Method and apparatus for monitoring a treatment of a patient, preferably for monitoring hemodialysis, hemodiafiltration, and/or peritoneal dialysis | |
US9423338B2 (en) | Apparatus and apparatus control method for the quantitative concentration determination of selected substances filtered out of a patient's body in a fluid | |
CN103228301B (en) | Device for extracorporeal blood treatment | |
US8125623B2 (en) | Correlation technique for analysis of clinical condition | |
WO2013186357A1 (en) | Method and device for monitoring an extracorporeal blood treatment of a patient | |
Roth et al. | Infrared spectroscopy in hemodialysis: reagent-free monitoring of patient detoxification by infrared spectroscopy | |
EP2585830B1 (en) | A method and device for determining content of the middle and protein bound uremic toxins in a biological fluid | |
WO2009071102A1 (en) | Optical method and device for measuring concentrations of substances in biological fluids | |
Fridolin et al. | On-line monitoring of solutes in dialysate using wavelength-dependent absorption of ultraviolet radiation | |
US20240102930A1 (en) | Multiparametric Optical Method and Device for determining Uremic Solutes, including Uremix Toxins, in Biological Fluids | |
Uhlin et al. | Optical monitoring of dialysis dose | |
Holmar et al. | Quantification of indoxyl sulphate in the spent dialysate using fluorescence spectra | |
Tomson et al. | Development of a method for optical monitoring of creatinine in the spent dialysate | |
Kondepati et al. | Infrared transmission spectrometry for the determination of urea in microliter sample volumes of blood plasma dialysates | |
Holmar et al. | Beta2-microglobulin measurements in the spent dialysate using fluorescence spectra | |
LAURI | Elimination of Uremic Toxins during Dialysis assessed with the Optical and Analytical Methods | |
Jerotskaja et al. | Improved optical method for measuring concentration of uric acid removed during dialysis | |
Lagali et al. | Hemodialysis monitoring in whole blood using transmission and diffuse reflection spectroscopy:<? xpp qa?> a pilot study | |
Paats et al. | Online Uric Acid Concentration Estimation in Blood from Spent Dialysate Measurements Using an Optical Sensor | |
Jerotskaja et al. | An enhanced optical method for measuring concentration of uric acid removed during dialysis | |
Lee et al. | Advances in uremic toxin detection and monitoring in the management of chronic kidney disease progression to end-stage renal disease | |
Jerotskaja et al. | A multicentre study of an enhanced optical method for measuring concentration of uric acid removed during dialysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121225 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180615 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190103 |